Published in
Massachusetts Medical Society, New England Journal of Medicine, 9(369), p. 819-829
Links
Tools
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
Journal article published in 2013 by
Teresa Coelho,
David Adams,
Ana Silva,
Pierre Lozeron,
Pn Hawkins 
,
Timothy Mant,
Javier Perez,
Joseph Chiesa,
Steve Warrington,
Elizabeth Tranter,
Malathy Munisamy,
Rick Falzone,
Jamie Harrop,
Jeffrey Cehelsky,
Br Bettencourt
and other authors.
,
Timothy Mant,
Javier Perez,
Joseph Chiesa,
Steve Warrington,
Elizabeth Tranter,
Malathy Munisamy,
Rick Falzone,
Jamie Harrop,
Jeffrey Cehelsky,
Br Bettencourt
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Data provided by 
Abstract
Transthyretin amyloidosis is caused by the deposition of hepatocyte-derived transthyretin amyloid in peripheral nerves and the heart. A therapeutic approach mediated by RNA interference (RNAi) could reduce the production of transthyretin.